Oculis Revenue

Biotechnology Research • Lausanne, Vaud, Switzerland • 51-100 Employees

Oculis revenue & valuation

Annual revenue	$1,044,963
Revenue per employee	$18,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$3,400,000
Total funding	No funding

Key Contacts at Oculis

Luke Zack

Senior Director, Global Regulatory Affairs Strategy

Petra Egger

Executive Legal Director

Gudrun Bachmann

Chief Technology Officer

Johannes Van Gelderen

Director, Regulatory Affairs

Will Caron

Director Of Financial Planning And Analysis

Nicola Parr

Director Quality Assurance - Cro

Eric Wuyq

Director Of Financial Planning And Analysis

Maxime Petetot

Senior Director Cmc

Samia Reffas Jobin

Senior Director, Head Of Pharmacovigilance

Jennifer Cerami

Senior Director Clinical Operations

Company overview

Headquarters	Avenue de la Gare 39, Lausanne, Switzerland 1003, CH
Phone number	+41588100182
Websites	oculis.com oculispharma.com
NAICS	541714
SIC	283
Keywords	Pharmaceutical, Biotech, Drug Delivery, Ophthalmology
Founded	2017
Employees	51-100
Socials

Oculis Email Formats

Oculis uses 4 email formats. The most common is {first name}.{last name} (e.g., john.doe@oculis.com), used 57.1% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@oculis.com	57.1%
{first initial}.{last name}	j.doe@oculis.com	38.1%
{first initial}	j@oculis.com	2.4%
{first initial}.{first3}{last name}	j.{first3}doe@oculis.com	2.4%

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a neuroprotective candidate for acute optic neuritis (AON). Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculis’ goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors. For more information, please visit: www.oculis.com

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Director

Manager

C-Suite

Employees by Department

Oculis has 29 employees across 6 departments.

Departments

Number of employees

Funding Data

Oculis has never raised funding before.

Oculis Tech Stack

Discover the technologies and tools that power Oculis's digital infrastructure, from frameworks to analytics platforms.

Cloudflare Bot Management

Security

Gravity Forms

Form builders

WP Rocket

Caching

Cookie Control

Cookie compliance

Swiper

JavaScript libraries

Microsoft 365

Cloudflare

CDN

jQuery

JavaScript libraries

HTTP/3

Miscellaneous

PHP

Programming languages

WordPress

Blogs

Google Analytics

Analytics

Frequently asked questions

Oculis is located in Lausanne, Vaud, CH.

You can reach Oculis at +41588100182.

Oculis generates an estimated annual revenue of $1,044,963. This revenue figure reflects the company's market position and business performance in its industry.

Oculis has an estimated valuation of $3,400,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Oculis was founded in 2017, making it 9 years old. The company has established itself as a significant player in its industry over this time.

Oculis has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.